Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 5;12(13):1784. doi: 10.3390/cells12131784

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Summary of possibly therapeutic interactions of ADSCs with fibroblasts and endothelial cells from scleroderma. (A) Single-cell analyses of chronic inflammatory diseases [9] and scleroderma [8] identified a proinflammatory CCL19⁺ and a SPARC⁺/COL3A1⁺ fibroblast subset that colocalises with the vasculature, highlighting the importance of the perivascular inflammation hub for activation of fibroblasts in scleroderma. (B) Based on differences and commonalities in cell-to-cell receptor–ligand interactions of ADSCs with fibroblasts and endothelial cells from healthy and scleroderma skin, VEGFD, MMP2, NTN1, FNDC5, and FGF2 were identified as possible anti-fibrotic effector molecules. Created with BioRender.com.